Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. (22nd September 2017)

• Record Type: Journal Article
• Authors: Zimmerman, Ofer; Rösler, Berenice; Zerbe, Christa S; Rosen, Lindsey B; Hsu, Amy P; Uzel, Gulbu; Freeman, Alexandra F; Sampaio, Elizabeth P; Rosenzweig, Sergio D; Kuehn, Hye Sun; Kim, Tiffany; Brooks, Kristina M; Kumar, Parag; Wang, Xiaowen; Netea, Mihai G; van de Veerdonk, Frank L; Holland, Steven M
• Is Part Of: Open forum infectious diseases. Volume 4:Number 4(2017)
• Publication Date: 2017-09-22
• Subjects: STAT1 -- gain of function -- ruxolitinib -- coccidiomycosis -- dermatophytosis; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx202
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.